BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Grass Care Administrations for a Wonderful, Sound Yard - 2Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- 3Dick Van Dyke shares his secrets to longevity as he turns 100
- 4More people are addicted to marijuana, but fewer of them are seeking help, experts say
- 5Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- UK clothing inflation climbs as Middle East turmoil threatens wider price rises
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
- Surveys of Music Collections by Film Stars
- How to sound like an astronaut as you follow the first human moon mission in more than half a century
- Report in relation to renaming Herzog Park set to be withdrawn
- 10 Energizing Vocations in the Innovation Business
- Somalia set for 'historic' first offshore oil drilling
